Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of Voquezna (vonoprazan)… read more.
New research presented at the Association of Anaesthetists Annual Meeting in Liverpool, UK (16-18 September) and published in the Association’s journal Anaesthesia shows that, for patients undergoing surgical… read more.
AbbVie announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) for subcutaneous (SC) induction for the treatment of adult… read more.
Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade after, according to a nationwide… read more.
The American Gastroenterological Association (AGA) today announced the launch of Nigel, an artificial intelligence (AI)-powered virtual assistant developed exclusively for gastroenterology and hepatology. Built using AGA’s trusted clinical guidance and developed in collaboration… read more.
Breast milk helps shape the gut microbiota for longer than previously thought. Researchers from DTU and Rigshospitalet have discovered that sugars in breast milk, which are nondigestible by… read more.
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented… read more.
Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes’ connections to their marketed use, new… read more.
Ironwood Pharmaceuticals announced that the FDA has approved the use of Linzess (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). Linzess was… read more.
New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn’s disease. These data… read more.
AbbVie announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18… read more.
In a new study published in Clinical Gastroenterology and Hepatology, the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel syndrome with diarrhea (IBS-D). Researchers also observed distinct… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
